Tafamidis meglumine

From WikiMD.org
Jump to navigation Jump to search

Tafamidis Meglumine

Tafamidis Meglumine (pronunciation: ta-fa-mi-dis me-glu-mine) is a medication used in the treatment of transthyretin amyloid cardiomyopathy and transthyretin familial amyloid polyneuropathy. It is a transthyretin stabilizer that works by slowing the progression of these diseases.

Etymology

The name "Tafamidis" is derived from the drug's mechanism of action, as it targets and stabilizes the transthyretin protein. "Meglumine" refers to the salt form of the drug, which enhances its solubility and absorption in the body.

Usage

Tafamidis Meglumine is used to treat transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare, progressive, and fatal disease characterized by the buildup of abnormal transthyretin protein in the body. It is also used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that affects the heart's structure and function due to the buildup of amyloid deposits.

Related Terms

  • Transthyretin: A protein in the blood that carries thyroid hormones and retinol. Mutations in the transthyretin gene can lead to the formation of abnormal protein deposits in various tissues and organs, causing conditions like TTR-FAP and ATTR-CM.
  • Amyloidosis: A group of diseases characterized by the buildup of amyloid proteins in various tissues and organs. TTR-FAP and ATTR-CM are types of amyloidosis.
  • Cardiomyopathy: A disease of the heart muscle that makes it harder for the heart to pump blood to the rest of the body. ATTR-CM is a type of cardiomyopathy.
  • Polyneuropathy: A condition that affects multiple peripheral nerves. TTR-FAP is a type of polyneuropathy.

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski